Free shipping on all orders over $ 500


Cat. No. M1701
Dasatinib Structure


Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 50  USD50 In stock
10mg USD 21  USD21 In stock
50mg USD 66  USD66 In stock
100mg USD 90  USD90 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

Dasatinib (BMS-354825) is a small molecule inhibitor of both the SRC and BCR/ABL tyrosine kinases, with IC50's for the isolated kinases of 0.55 and 3.0 nM, respectively. Dasatinib also inhibits Lyn (IC50 = 8.5 nM) and Src (IC50 = 3.0 nM) kinase activities in vitro using 0.1 mg/mL poly (Glu4-Tyr) as the substrate. Dasatinib has greater potency than imatinib mesylate and has activity against the majority of kinase mutations in imatinib-resistant chronic myeloid leukemia.

Product Citations
Customer Product Validations & Biological Datas
Source Biochimica et Biophysica Acta (2017) . Figure 7. Dasatinib was supplied from Abmole Bioscience (Houston, TX, USA).
Method Flow cytometry
Cell Lines MDA-MB-231 cells
Concentrations 20 μM
Incubation Time 24 h
Results Apoptosis analysis by flow cytometry showed that shCtrl- and shCav-1-transfected MDA-MB-231 cells treated with Dasatinib for 24 h maintained high cell viability (N80%), with no disparity in apoptosis (Fig. 7B).
Cell Experiment
Cell lines Ba/F3 cell lines
Preparation method Cellular proliferation assays. Ba/F3 cell lines were plated in triplicate and incubated with escalating concentrations of imatinib, AMN107, or BMS-354825 for 72 hours. Proliferation was measured using a methanethiosulfonate-based viability assay (CellTiter96 Aqueous One Solution Reagent; Promega). IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges for IC50 and IC90 determinations were 0 to 2,000 nmol/L (imatinib and AMN107) or 0 to 32 nmol/L (BMS-354825). The imatinib concentration range was extended to 6,400 nmol/L for mutants with IC50 >2,000 nmol/L. The BMS-354825 concentration range was extended to 200 nmol/L for mutant T315I.
Concentrations 0~2000nM
Incubation time 72 h
Animal Experiment
Animal models primary human Ph+ B-ALL xenografts
Formulation dissolved in a mixture of polypropylene glycol (Sigma-Aldrich) diluted in water (50:50)
Dosages 5 mg/kg/day for two weeks
Administration oral gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 488.01
Formula C22H26ClN7O2S
CAS Number 302962-49-8
Purity 99.91%
Solubility DMSO 68 mg/mL
Storage at -20°C

[1] Sano et al. Intern Med. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia critical alert.

[2] Yang et al. Blood. Anti-tumor T cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.

[3] Radich et al. Blood. A randomized trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic phase chromic myeloid leukemia.

[4] Sharma et al. Asia Pac J Clin Oncol. Dasatinib in chronic myeloid leukemia: A limited Indian experience.

[5] Agarwal et al. Mol Cancer Ther. Active efflux of dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly-targeted agents.

[6] Birch et al. Biomed Chromatogr. Simple methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib.

[7] Noy et al. Leuk Res. Dasatinib inhibits leukaemic cell survival by decreasing PRH/Hhex phosphorylation resulting in increased repression of VEGF signalling genes.

[8] Kralj et al. J Chromatogr B Analyt Technol Biomed Life Sci. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.

[9] Kuckertz et al. Onkologie. Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.

Related Src-bcr-Abl Products

1NM-PP1 is a cell-permeable and potent Src family kinases inhibitor with IC50 values of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively.


TL02-59 is a selective, orally active Src-family kinase Fgr inhibitor with IC50 of 0.03 nM, it also inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively.


CZC-8004 is a pan-kinase inhibitor and binds a range of tyrosine kinases, including ABL kinase.

Flumatinib mesylate

Flumatinib mesylate is a selective inhibitor of BCR-ABL/PDGFR/c-Kit with IC50s of 1.2 nM, 307.6 nM and 2662 nM, respectively.


Asciminib, also known as ABL001, is a potent allosteric inhibitor of BCR-ABL, with a Kd value of 0.5-0.8 nM.

Abmole Inhibitor Catalog 2017

Keywords: Dasatinib, BMS-354825 supplier, Src-bcr-Abl, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.